LD-2 disclosure · 2nd Quarter - Report
NOVARTIS, INC.
Client
- Name
- NOVARTIS, INC.
- Description
- ​Multinational biopharmaceutical company.
- Location
- District of Columbia · United States of America
Registrant
- Description
- ​Government Affairs Consulting Firm.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesMedicare/Medicaid
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
LobbyistsDANIEL M TODD · PAUL EDATTEL · JEFF LUCAS · NICHOLAS UEHLECKE · TAYLOR SEXTON · TED LEHMAN · ERIC BERGREN · KIMBERLY LINTHICUM
TargetedSENATE · HOUSE OF REPRESENTATIVES · Health & Human Services, Dept of (HHS)
Tariff (miscellaneous tariff bills)
Traffic policies.
LobbyistsPAUL EDATTEL · JEFF LUCAS · NICHOLAS UEHLECKE · TAYLOR SEXTON · TED LEHMAN · ERIC BERGREN
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.
LobbyistsDANIEL M TODD · PAUL EDATTEL · JEFF LUCAS · NICHOLAS UEHLECKE · TAYLOR SEXTON · TED LEHMAN · ERIC BERGREN · KIMBERLY LINTHICUM